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ABSTRACT  
Functionally matured microRNAs (miRNAs) are small single-stranded non-coding RNA molecules which are 
emerging as important post-transcriptional regulators of gene expression and consequently are central players in 
many physiological and pathological processes. Since the biological roles of individual miRNAs will be dictated 
by the mRNAs that they regulate, the identification and validation of miRNA/mRNA target interactions is criti-
cal for our understanding of the regulatory networks governing biological processes. We promulgate the com-
bined use of prediction algorithms, the examination of curated databases of experimentally supported miR-
NA/mRNA interactions, manual sequence inspection of cataloged miRNA binding sites in specific target 
mRNAs, and review of the published literature as a reliable practice for identifying and prioritizing biologically 
important miRNA/mRNA target pairs. Once a preferred miRNA/mRNA target pair has been selected, we pro-
pose that the authenticity of a functional miRNA/mRNA target pair be validated by fulfilling four well-defined 
experimental criteria. This review summarizes our current knowledge of miRNA biology, miRNA/mRNA target 
prediction algorithms, validated miRNA/mRNA target data bases, and outlines several experimental methods by 
which miRNA/mRNA targets can be authenticated. In addition, a case study of human endoglin is presented as 
an example of the utilization of these methodologies. 
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INTRODUCTION 
MicroRNAs (miRNAs) are an endoge-
nous family of single-stranded 20–25 nu-
cleotide non-coding RNAs that play a critical 
role in posttranscriptional gene regulation by 
acting as guide molecules for the miRNA-
induced silencing complex (miRISC) to in-
hibit gene expression by targeting specific 
mRNAs for translational inhibition and/or 
degradation (reviewed in Bartel, 2009; Fabi-
an et al., 2010; Fabian and Sonenberg, 2012; 
Ha and Kim, 2014; Wilson and Doudna, 
2013). Newer regulatory roles for miRNAs 
have also been documented, including miR-
NA mediated induction of gene expression 
(reviewed in Valinezhad Orang et al., 2014; 
Vasudevan, 2012). 
Currently, 2,588 mature miRNAs pro-
cessed from 1,881 precursor miRNAs have 
been annotated in the human genome (miR-
Base: http://www.mirbase.org/index.shtml, 
release #21, June 14 2014). It is now clear 
that the expression levels of miRNAs vary 
widely; some are ubiquitously expressed, 
while others are expressed in a tissue- and/or 
cell-specific manner, and many show spatio-
temporal expression patterns (Hausser et al., 
2009; Landgraf et al., 2007; Moreau et al., 
2013). Importantly, individual miRNAs can 
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act upon numerous target mRNAs and every 
mRNA can be targeted by multiple miRNAs; 
allowing for enormous combinatorial com-
plexity and regulatory potential (Balaga et 
al., 2012; Dombkowski et al., 2011; Fried-
man et al., 2014; Gurtan and Sharp, 2013). 
Computational predictions suggest that more 
than 60 % of all human protein-coding 
mRNAs harbor at least one conserved miR-
NA-binding site, and many more mRNAs 
contain non-conserved miRNA binding posi-
tions, suggesting that the protein expression 
levels of the majority of human genes may 
be regulated by miRNAs (Friedman et al., 
2009). Therefore, it is not surprising that 
miRNAs play an integral role in almost all 
known biological processes (reviewed in 
Bartel, 2009; Fabian et al., 2010). Although 
miRNAs are thought to “fine-tune” gene ex-
pression since they generally repress protein 
levels less than 20 % (Baek et al., 2008; Bar-
tel, 2009; Selbach et al., 2008), recent stud-
ies suggest that miRNA function becomes 
more pronounced in response to physiologic 
and pathophysiologic stresses (reviewed in 
Leung and Sharp, 2010; Mendell and Olson, 
2012). 
 
miRNA BIOGENESIS 
The vast majority of functional miRNAs 
are produced by a canonical multistep bio-
genic process which is initiated in the nucle-
us and is completed in the cytoplasm (Figure 
1) (reviewed in Ha and Kim, 2014; Krol et 
al., 2010; Wilson and Doudna, 2013). 
Mammalian miRNAs are embedded in pri-
mary miRNA transcripts (pri-miRNAs) 
which are 5′ 7-methylguanosine-capped 
(m7G-capped) and polyadenylated at their 3′ 
ends (Cai et al., 2004; Lee et al., 2004). Typ-
ically, pri-miRNAs are transcribed by RNA 
polymerase II from independent genes or 
from introns of protein-coding genes (Figure 
1) (Cai et al., 2004; Lee et al., 2004).  
During the transcriptional process, pri-
miRNAs fold into secondary configurations 
containing imperfectly base-paired stem-
loops in which the mature miRNA sequences 
are embedded (Figure 1). Importantly, these 
hairpins serve as substrates for the Micro-
processor complex (Figure 1). The Micro-
processor complex is comprised of at least 
two proteins, Drosha (i.e., RNase III-type 
endonuclease) and its binding partner 
DGCR8 (DiGeorge syndrome critical region 
8 gene) (Denli et al., 2004; Gregory et al., 
2004; Han et al., 2004; Lee et al., 2003). 
DGCR8 is the Microprocessor component 
that directly interacts with pri-miRNAs 
through two double stranded RNA-binding 
domains (dsRBD) (Han et al., 2006), while 
it’s C-terminus interacts with Drosha (Yeom 
et al., 2006). Drosha initiates the endonucle-
olytic cleavage of the stem–loop to release a 
“cropped” hairpin structured precursor miR-
NA (pre-miRNA) of ~60-70 nucleotides in 
length (Figure 1) (Lee et al., 2003). Follow-
ing Drosha/DGCR8 processing, the pre-
miRNAs are bound by Exportin-5 (EXP5; 
encoded by the XPO5 gene) and a nuclear 
pore complex is formed with the GTP-
binding nuclear protein, Ran-GTP (Figure 1) 
(Bohnsack et al., 2004; Lund et al., 2004; Yi 
et al., 2003). Once the pre-miRNA is trans-
ported through the nuclear pore complex, 
GTP is hydrolyzed, the complex is disas-
sembled, and the pre-miRNA is released into 
the cytoplasm. Subsequent to export from 
the nucleus, Dicer (another RNase III type 
enzyme) with its co-factor dsRBD protein, 
TRBP (TAR RNA-binding protein) (Chen-
drimada et al., 2005) or PACT (protein acti-
vator of PKR) (Lee et al., 2006), cleaves pre-
miRNAs near the terminal loop resulting in 
miRNA duplexes of ~22 nucleotides (Figure 
1) (reviewed in Ha and Kim, 2014; Krol et 
al., 2010; Wilson and Doudna, 2013). The 
miRNA duplex is then released by Dicer and 
loaded onto Argonaute (AGO) protein 
which, together with the trinucleotide repeat 
containing 6A protein (TNRC6A/GW182), 
form the core of the miRISC (reviewed in 
Fabian and Sonenberg, 2012; Ha and Kim, 
2014; Krol et al., 2010; Wilson and Doudna, 
2013).  
During the AGO loading step, strand se-
lection takes place and typically, the strand 
with the least thermodynamically stable base 
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Figure 1: Mechanisms involved in miRNA biogenesis. This diagram includes miRNA transcription, 
maturation of miRNA/mRNA and two potential mechanisms for miRNA/mRNA silencing. The specific 
details describing these processes have recently been extensively reviewed (Fabian and Sonenberg, 
2012; Ha and Kim, 2014; Krol et al., 2010; Wilson et al., 2013) and are briefly discussed in the text. 
 
pair at its 5′ end in the miRNA duplex is se-
lected as the “guide strand” (a single-
stranded 20–25 nucleotide functional mature 
miRNA) and is retained within the miRISC 
(Figure 1) (Khvorova et al., 2003; Schwarz 
et al., 2003). In contrast, the “passenger 
strand” (also referred to as the complemen-
tary star-form miRNA strand or miRNA*) is 
released from miRISC and is subsequently 
degraded (Khvorova et al., 2003; Schwarz et 
al., 2003). It is important to note that passen-
ger strands (miRNA*) are not always miR-
NA biogenic waste-products and they too 
can be loaded into miRISC, and exhibit in-
hibitory activity like any other miRNA 
(Chiang et al., 2010; Okamura et al., 2008; 
Packer et al., 2008; Yang et al., 2011). Given 
the increasing number of examples of “arm 
switching”, where two distinct functional 
mature miRNAs (guide strands) can be pro-
cessed from opposite arms of the same pre-
miRNA, these products are now denoted 
with the suffix -5p (from the 5′ arm) (e.g. 
miR-370-5p) or -3p (from the 3′ arm) (e.g. 
miR-370-3p) following their name. For more 
information regarding miRNA nomenclature 
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as adopted by the miRNA Registry please 
see http://www.mirbase.org/help/nomencla-
ture.shtml (Ambros et al., 2003). 
 
miRNA/mRNA SILENCING 
After the mature miRNA is assembled 
into the miRISC, the guide strand targets this 
protein complex to specific mRNAs through 
a diffusion-controlled mechanism where the 
guide strand continuously binds/dissociates 
from mRNAs until a thermodynamically fa-
vorable binding site (i.e., miRNA recogni-
tion element, MRE) is found (Brown et al., 
2005). Importantly, this mechanism is facili-
tated when the guide strand has greater ac-
cess to a given MRE harbored in a specific 
mRNA (Brown et al., 2005). The association 
of miRNA with a specific mRNA target (i.e. 
miRNA:mRNA hybridization) involves a 
two-step process in which a miRNA anneals 
to a MRE and the mRNA structure then un-
folds as the miRNA completes binding to a 
mRNA target (Long et al., 2007). 
With few exceptions, MREs are primari-
ly located in the 3′-untranslated region (3′-
UTR) of mRNAs and once recognized, ma-
ture miRNAs imperfectly base pair with 
MREs following a set of rules which have 
been experimentally and computationally 
identified (Brennecke et al., 2005; Doench 
and Sharp, 2004; Grimson et al., 2007; Lew-
is et al., 2005; Nielsen et al., 2007). First, 
miRNA/mRNA target recognition involves 
Watson-Crick base pairing that must be per-
fect and contiguous at the 5′-end of the 
miRNA from nucleotides 2 to 7 and com-
plementary to nucleotides in the 3′-UTR of 
mRNAs (Brennecke et al., 2005; Doench and 
Sharp, 2004; Lewis et al., 2005). This zone 
represents the “seed” region and nucleates 
the miRNA-mRNA association. Second, a 
match to positions 2 to 7 of a miRNA (a 
6mer seed match) usually has only a small 
effect on target mRNAs unless the seed se-
quence is flanked by a Watson–Crick match 
opposite position 8 (a 7mer-m8), an adeno-
sine opposite position 1 (a 7mer-A1), or both 
(an 8mer) (Grimson et al., 2007; Nielsen et 
al., 2007). Third, the sequence context of the 
MREs in target mRNAs, also influence the 
functional importance of these sites (Grim-
son et al., 2007; Nielsen et al., 2007). For 
example, MREs harbored in the 5′-UTRs 
and/or open reading frames (ORFs) are much 
less effective as target sequences within 
these mRNAs for translational inhibition 
and/or degradation than those found in 3′-
UTRs presumably because scanning or trans-
lating ribosomes interfere with miRISC 
binding (Grimson et al., 2007). Additionally, 
miRNA efficacy can be improved if the 
MRE site is positioned within an AU-rich 
sequence region and not located in the mid-
dle of long unstructured 3′-UTRs probably 
reflecting areas in mRNAs less accessible to 
the miRISC (Grimson et al., 2007; Kertesz et 
al., 2007; Nielsen et al., 2007). Finally, mul-
tiple MREs that are located within the same 
3′-UTR tend to multiplicatively affect 
mRNA down-regulation via miRNA/mRNA 
binding (Grimson et al., 2007). Specifically, 
when MREs are located within 8 to 40 nu-
cleotides of each other, then miRNAs tend to 
act cooperatively, providing a potent in-
crease in miRISC efficacy (Grimson et al., 
2007). Interestingly, MREs for a specific 
miRNA located in ORFs can also enhance 
regulation mediated by the same miRNA 
targeted MREs in 3′-UTRs (Fang and Ra-
jewsky, 2011). 
After miRNA/mRNA target recognition, 
miRISC-bound target mRNAs are subjected 
to translational repression (i.e. inhibition of 
translation initiation) and/or deadenylation, 
decapping, and subsequent decay by a num-
ber of silencing factors that are scaffolded to 
this complex by TNRC6A/GW182 (Figure 
1) (reviewed in Fabian and Sonenberg, 
2012). Importantly, global ribosome profil-
ing studies which can precisely compare 
changes in translational efficiency to changes 
in mRNA levels, demonstrate that regardless 
of the miRNA, cell type, growth condition, 
or translational state, the majority of the neg-
ative post-transcriptional gene regulatory ef-
fects of miRNAs/miRISCs occur through 
mRNA decay (66 % - > 90 %) (Eichhorn et 
al., 2014). 
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One major question regarding miRNA 
function that has not been adequately ad-
dressed is how miRNA concentration relates 
to target mRNA suppression. Several studies 
have suggested that only highly expressed 
miRNAs are able to mediate negative post-
transcriptional gene regulatory effects 
(Brown et al., 2007; Hafner et al., 2010; 
Mullokandov et al., 2012). For example, 
Mullokandov et al. (2012) demonstrated that 
60 % of the miRNAs detected by deep-
sequencing had no discernible suppressive 
activity using a Sensor-seq assay which sup-
ported their earlier observation that miRNAs 
expressed below ~100 copies per cell had lit-
tle regulatory capacity (Brown et al., 2007). 
Finally, competitive endogenous RNAs 
(ceRNAs), which include transcripts with 
multiple MREs such as pseudogenes, long 
noncoding RNAs (lncRNAs), and miRNAs 
are now considered to be natural decoys or 
sponges which compete for common miR-
NAs and can therefore influence the expres-
sion levels of multiple miRNAs (reviewed in 
Salmena et al., 2011). It is now hypothesized 
that miRNAs and ceRNAs can regulate each 
other in extended cross-talk networks and 
may play a major role in complex physiolog-
ical processes and disease states (Salmena et 
al., 2011).  
 
miRNA/mRNA TARGET PREDICTION 
ALGORITHMS 
Given the large number of potential 
MREs harbored within any mRNA, compu-
tational miRNA/mRNA target algorithms are 
the most practical and efficient methods for 
identifying putative miRNA/mRNA interac-
tions and selecting potential target sites for 
hypothesis conception and subsequent exper-
imental validation (Alexiou et al., 2009). 
There are a wide variety of prediction algo-
rithms available to investigators that encom-
pass a range of different computational ap-
proaches; however, the main prediction fea-
tures include experimentally determined 
miRNA/mRNA pairing criteria necessary for 
optimal silencing (see above section). These 
include seed sequence match (Brennecke et 
al., 2005; Grimson et al., 2007; Krek et al., 
2005; Lewis et al., 2003, 2005; Nielsen et 
al., 2007), seed sequence conservation (Lew-
is et al., 2003), target site accessibility (Ma-
hen et al., 2010), target site context (Grimson 
et al., 2007; Kertesz et al., 2007; Nielsen et 
al., 2007), and free energy calculations (Yue 
et al., 2009). Recently, prediction algorithms 
have also begun to implement machine 
learning approaches utilizing training data 
sets based on experimental information that 
represent positive and negative interactions 
to develop models of miRNA/mRNA target-
ing (Chi et al., 2009; Hafner et al., 2010). 
These models are subsequently utilized as 
part of the miRNA/mRNA target prediction 
process (Vlachos and Hatzigeorgiou, 2013). 
Due to the differences in the computational 
approaches described above, the predicted 
miRNA/mRNA targets vary widely depend-
ing upon which algorithm is employed. How, 
therefore, can a research investigator deter-
mine which algorithm(s) should be utilized 
to identify potential miRNA/mRNA targets?  
To begin to address this critical question, 
several recent review articles have compared 
and contrasted many of the miRNA/mRNA 
target algorithms currently available (Alex-
iou et al., 2009; Dweep et al., 2013; Peterson 
et al., 2014; Reyes-Herrera and Ficarra, 
2012; Vlachos and Hatzigeorgiou, 2013). 
For example, in their original publication, 
Alexiou et al. (2009) compared eight of the 
most commonly used human and mouse 
miRNA/mRNA target algorithms and sug-
gested that, based on precision and sensitivi-
ty levels, that the top four algorithms were; 
DIANAmicroT 3.0 (http://microrna.gr/mi-
croT) (Maragkakis et al., 2009), TargetScan 
(http://www.targetscan.org) (Friedman et al., 
2009), Pictar (http://pictar.org) (Lall et al., 
2006), and ElMMo (http://www.mirz.uni-
bas.ch) (Gaidatzis et al., 2007). The latest re-
view article from this laboratory (Vlachos 
and Hatzigeorgiou, 2013) provided a detailed 
overview of the major miRNA/mRNA target 
computational approaches utilized by Tar-
getScan (http://www.targetscan.org, release 
6.2, based on miRBase Release 17) (Garcia 
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et al., 2011; Grimson et al., 2007), DIANA-
microT-CDS (http://www.microrna.gr/mi-
croT-CDS, 5th version, based on miRBase 
Release 18) (Paraskevopoulou et al., 2013; 
Reczko et al., 2012), and the miRanda-
mirSVR algorithm (http://microrna.org, a da-
tabase of predicted miRNA/mRNA targets 
based on miRBase Release 15) (Betel et al., 
2010). Additionally, Peterson et al. (2014) 
recently concluded that, based on ease of 
use, range of capabilities, and relatively cur-
rent input data, and maintenance of the soft-
ware, the utilization of DIANA-microT-
CDS, miRanda-mirSVR, or TargetScan was 
preferred for miRNA/mRNA target predic-
tions. Given that only Diana-microT-CDS 
(Reczko et al., 2012) and TargetScan (Garcia 
et al., 2011; Grimson et al., 2007) have been 
updated and significantly modified in the 
past several years, we advocate the use of 
these two algorithms to predict human and 
mouse miRNA/mRNA targets. Due to the 
rapid discovery rate of novel miRNAs (2,588 
annotated human mature miRNAs, miRBase 
Release 21, http://www.mirbase.org) even 
these two algorithms would benefit from 
more current data input.  
It is also significant to note that updated 
algorithms identify up to 60 % of all availa-
ble miRNA/mRNA targets and provide only 
one valid target in approximately every three 
predicted targets (Vlachos and Hatzigeor-
giou, 2013). It is evident, therefore, that even 
the best available algorithms still fail to iden-
tify a significant number of biologically im-
portant miRNA/mRNA targets (Reczko et 
al., 2012). For example, several recent stud-
ies have demonstrated that non-canonical 
miRNA interactions are diverse, functional, 
much more prevalent than previously appre-
ciated, and cannot be identified by any cur-
rent algorithm (Grosswendt et al., 2014; 
Helwak et al., 2013; Martin et al., 2014; Tan 
et al., 2014).  
 
miRNA/MRNA TARGET PREDICTION 
ALGORITHM ANALYSES:  
ENDOGLIN AS AN EXAMPLE  
Given the above review of miRNA biol-
ogy and miRNA/mRNA target prediction al-
gorithms, we propose the following “work 
flow” scheme (Figure 2) for the identifica-
tion and validation of miRNA/mRNA target 
interactions. First, the investigator must 
choose a gene target or miRNA of interest to 
investigate. 
For a case study we have chosen to ana-
lyze the human endoglin gene (ENG) for po-
tential MREs. Endoglin (CD 105, TGF-β re-
ceptor III) is a homodimeric co-receptor for 
transforming growth factor beta (TGFβ) and 
is known to play a regulatory role in TGFβ 
signaling (reviewed in Kapur et al., 2013; 
López-Novoa and Bernabeu, 2010; Nach-
tigal et al., 2012; Rosen et al., 2014). It has 
been demonstrated that endoglin plays a role 
in many pathological processes, including 
cancer, angiogenesis, hereditary hemorrhagic 
telangiectasia (HHT), pre-eclampsia, pulmo-
nary hypertension, heart failure, myocardial 
infarction, atrial fibrillation, atherosclerosis, 
and diabetes mellitus (Kapur et al., 2013; 
Lee et al., 2012b; López-Novoa and Berna-
beu, 2010; Nachtigal et al., 2012; Rosen et 
al., 2014). Given that miRNAs play an inte-
gral role in most physiologic and pathophys-
iologic conditions (reviewed in Acunzo et 
al., 2015; Adams et al., 2014; Arunachalam 
et al., 2015; Neppl and Wang, 2014), it is of 
interest to determine whether or not endoglin 
expression is aberrantly regulated by miR-
NAs in certain disease states. 
Once the gene target (in this case, en-
doglin) or miRNA of interest has been cho-
sen, it must then be analyzed by miR-
NA/mRNA target prediction algorithms 
(Figure 2). Both the Diana-microT-CDS 
(Paraskevopoulou et al., 2013; Reczko et al., 
2012) and TargetScan (Garcia et al., 2011; 
Grimson et al., 2007) algorithms allow the 
investigator to enter a specific ‘‘Gene Sym-
bol’’ or “miRNA”. The predicted MREs 
harbored within the mRNA or all of the 
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mRNAs which harbor a given MRE will 
then be computed.  
The Diana-microT-CDS algorithm re-
sults include; the identified miRNAs and 
their predicted location of MREs both in the 
coding sequences (CDS) and in the 3′-UTR, 
the seed sequence binding type, whether or 
not the predicted MRE is conserved (MREs 
that are conserved during evolution tend to 
be more biologically consequential com-
pared to those that haven't, Friedman et al., 
2009), what species harbor the conserved 
MRE, the miTG (miRNA targeted genes) 
targeting score (the higher the score the 
higher the probability of targeting MREs 
harbored within the CDS or in the 3′-UTR of 
the human S-endoglin mRNA), and whether 
or not a given miRNA target is also predict-
ed by the miRanda or TargetScan algorithms 
(Paraskevopoulou et al., 2013). It is essential 
to note that this algorithm (Diana-microT-
CDS) only analyzes the longest annotated 
transcript (i.e. the one with the longest 3′-
UTR sequence) for each gene (Ensembl ver-
sion 69, www.ensembl.org) (Paraskevopou-
lou et al., 2013). This is a crucial considera-
tion given that more than 90 % of human 
genes are estimated to undergo alternative 
splicing (Pan et al., 2008; Wang et al., 2008) 
and ∼70 % of all human genes contain mul-
tiple alternative cleavage and polyadenyla-
tion sites (Derti et al., 2012). Importantly, 
these post-transcriptional regulatory mecha-
nisms can result in mRNA isoforms that dif-
fer in CDS and/or in 3′-UTR length, and as a 
consequence, mRNA/miRNA target interac-
tion sites can be added or subtracted from 
each isoform (Boutet et al., 2012; Park et al., 
2011; Sandberg et al., 2008; Tan et al., 
2007). Therefore, it is recommended that one 
has a clear understanding whether the gene 
of interest is regulated by alternative RNA 
processing mechanisms before performing 
miRNA algorithm analyses. 
 
 
Figure 2: Proposed flow diagram for the identification of putative microRNA/mRNA target interactions, 
and subsequent hypothesis driven experimental validation of these predicted MREs. 
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Interestingly, the human ENG gene gen-
erates two distinct mRNAs through alterna-
tive splicing, which results in isoforms that 
differ in a portion of their CDS and 3′-UTR 
(Bellón et al., 1993; Pérez-Gómez et al., 
2005). The predominant human endoglin 
mRNA isoform is comprised of 15 exons, 
encodes a protein of 658 amino acids which 
has a cytoplasmic domain of 47 residues 
(long, or L-endoglin), and harbors a 670 nu-
cleotide (nt) 3′-UTR (Bellon et al., 1993). In 
contrast, the second human endoglin mRNA 
isoform is comprised of the same 15 exons, 
however, intron 14 is retained (Bellon et al., 
1993). The retention of intron 14 introduces 
a premature stop codon in the reading frame, 
therefore, this isoform encodes a protein of 
625 amino acids which contains a cytoplas-
mic tail of only 14 residues (short or S-
endoglin) and harbors a 905 nt 3′-UTR (Bel-
lon et al., 1993). The initial 235 nts of the 3′-
UTR are unique to this isoform and the re-
maining 670 nucleotides overlap with the en-
tire 3′-UTR of L-endoglin mRNA isoform 
(Bellon et al., 1993). Although both endoglin 
forms are able to bind ligand (Bellon et al., 
1993), it is assumed that the structural differ-
ences of their cytoplasmic domains account 
for the distinct functional effects observed 
for each isoform (Aristorena et al., 2014; 
Blanco et al., 2005, 2008, 2015; Velasco et 
al., 2008).  
Since the mRNA isoform which encodes 
S-endoglin harbors the longest 3′-UTR, the 
Diana-microT-CDS algorithm will only uti-
lize this sequence for computing miR-
NA/endoglin mRNA target interactions. 
When this analysis is performed, a total of 
259 (threshold set to 0.4) miRNAs are pre-
dicted to interact with the human S-endoglin 
mRNA isoform at 797 individual MREs, 
with 186 target sites located in the CDS and 
611 sites in the 3′-UTR (data not shown). 
Table 1 lists the top fifteen Diana-microT-
CDS predicted miRNAs to interact with this 
mRNA isoform, and includes the number of 
predicted MREs and locations, and their re-
spective miTG scores. Although 596 of the 
611 predicted human S-endoglin MREs har-
bored in the 3′-UTR are conserved across at 
least one other species, this does not always 
mean that predicted target interactions are 
conserved between humans and lower spe-
cies such as rodents. This is a key considera-
tion given that in vivo miRNA/mRNA target 
validation experiments can’t be performed if 
these MREs are not conserved in mice (see 
experimental validation sections below). As 
a result, Table 1 includes whether any of the 
top fifteen identified miRNAs with predicted 
MREs harbored in the human S-endoglin 3′-
UTR are also conserved in the mouse Eng 
gene. Interestingly, of the 259 Diana-
microT-CDS identified miRNAs only 87 
bind to 98 predicted MREs that are con-
served in both the human and mouse 
ENG/Eng gene. It is also significant to note, 
however, that conservation of a miRNA 
binding site harbored in a given mRNA tar-
get is not a requirement for a functional 
miRNA (Witkos et al., 2011).  
In contrast to Diana-microT-CDS, the 
TargetScan algorithm results include the 
identified miRNAs and the predicted loca-
tion of MREs in the 3′-UTR but not in the 
CDS. However, this tool does allow the user 
to analyze any annotated splice variant for a 
given gene. For example, TargetScan will 
analyze both L-endoglin and S-endoglin 3′-
UTRs. The TargetScan results also include 
the number and type of seed match of con-
served and poorly conserved miRNA bind-
ing sites, and a total context score (predicted 
efficacy of targeting) (Garcia et al., 2011; 
Grimson et al., 2007). When the human S-
endoglin mRNA isoform (NM_000118, 905 
nt 3′-UTR) is analyzed by TargetScan, 152 
miRNAs and/or miRNA families are pre-
dicted to interact with 189 MREs in the 3′-
UTR. Table 2 lists the top fifteen TargetScan 
predicted miRNAs to interact with this 
mRNA isoform, and includes the number of 
predicted MREs, the number of highly con-
served MREs, the number of conserved 
mouse S-endoglin MREs, and their respec-
tive context scores.  When the human L-
endoglin mRNA isoform (NM_001114753, 
670 nt 3′-UTR) is analyzed by TargetScan, 
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Table 1: Top fifteen DIANA-microT-CDS predicted human miRNA/endoglin mRNA target interactions 
based on their targeting score 
miRNA # of predicted MREs Location 
# of predicted MREs 
conserved in mice miTG Score 
miR-3692-5p 4 4 x 3′-UTR 2 x 3′-UTR 0.980 
miR-3907 5 5 x 3′-UTR 2 x 3′-UTR 0.914 
miR-1285-5p 10 10 x 3′-UTR 1 x 3′-UTR 0.901 
miR-612 9 9 x 3′-UTR None 0.891 
miR-4486 9 9 x 3′-UTR None 0.885 
miR-876-3p 2 2 x 3′-UTR 1 x 3′-UTR 0.879 
miR-4674 7 7 x 3′-UTR None 0.873 
miR-342-5p 2 8 x 3′-UTR 2 x 3′-UTR 0.863 
miR-378g 9 8 x 3′-UTR1 x CDS None 0.858 
miR-4731-5p 8 7 x 3′-UTR1 x CDS None 0.841 
miR-4527 4 2 x 3′-UTR2 x CDS None 0.839 
miR-4268 8 8 x 3′-UTR 1 x 3′-UTR 0.821 
miR-330-5p 5 3 x 3′-UTR2 x CDS 1 x 3′-UTR 0.818 
miR-5189 10 10 x 3′-UTR 1 x 3′-UTR 0.818 
miR-629-3p 1 1 x 3′-UTR None 0.814 
 
Table 2: Top fifteen TargetScan predicted miRNA/S-endoglin mRNA target interactions based on their 
target score (Human, ENG, NM 000118, 3′-UTR length 905 nt) 
miRNA # of predict-ed MREs 
# of highly 
conserved 
MREs 
# of con-
served MREs 
in mice 
Total Context 
Score 
miR-1349/1389/378g 5 1 1 -0.73 
miR-762/4492/4498 2 0 0 -0.59 
miR-1587/3083/4505 3 0 1 -0.53 
miR-296-5p 2 0 0 -0.51 
miR-1915 2 1 0 -0.42 
miR-4649-5p 1 1 0 -0.41 
miR-4781-5p 2 0 0 -0.41 
miR-4437 3 0 0 -0.40 
miR-4486 3 0 0 -0.40 
miR-608/1331/4651 1 1 0 -0.38 
miR-4715-3p 1 0 0 -0.37 
miR-1669/4674 3 0 0 -0.37 
miR-1825 2 0 0 -0.35 
miR-4690-5p 2 0 0 -0.32 
miR-486-3p 2 1 0 -0.30 
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132 miRNAs and/or miRNA families are 
predicted to interact with 162 MREs in the 
3′-UTR. Table 3 lists the top fifteen Tar-
getScan predicted miRNAs to interact with 
this mRNA isoform and includes the same 
information as shown in Table 2. The data 
shown in these two tables is very similar, 
however, due to differences in the lengths of 
the analyzed 3′-UTRs the “target site con-
text” (Grimson et al., 2007) differs and this 
leads to changes in their total context scores 
and therefore the order of the predicted 
miRNAs.  
Given that the initial 235 nts of the hu-
man S-endoglin mRNA 3′-UTR are unique 
to this isoform, Targetscan identified 20 
miRNAs and/or miRNA families that are 
predicted to target 20 MREs located only in 
this region (Table 4) and an additional 7 
miRNAs and/or miRNA families that are 
predicted to interact with MREs located in 
this unique 3′-UTR region and in the 3′-UTR 
region common to both human endoglin 
mRNA isoforms (Table 5). It is possible to 
utilize the lists shown in Tables 4 and 5 to 
devise an experimental hypothesis regarding 
potential miRNA regulatory differences be-
tween human S- and L-endoglin mRNAs. 
As described earlier, one of the parame-
ters computed by the Diana-microT-CDS al-
gorithm is whether or not a given miR-
NA/mRNA target is also predicted by the 
TargetScan algorithm (Paraskevopoulou et 
al., 2013). Interestingly, this algorithm found 
that only 18 of the predicted 259 miRNAs 
overlapped with miRNAs computed by Tar-
getScan to interact with human endoglin 
mRNAs. However, by direct (manual) com-
parison of the miRNA/endoglin mRNA tar-
get site interactions computed by the Diana-
microT-CDS and TargetScan algorithms, 
over 50 % of these sites overlapped (data not 
shown). Table 6 lists the top 20 miRNAs 
and/or miRNA families predicted by both al-
gorithms based on targeting scoring. Im-
portantly, this list of miRNAs predicted by 
both algorithms to target human endoglin 
mRNAs can be utilized to begin to formulate 
experimental hypotheses. 
 
Table 3: Top fifteen TargetScan predicted miRNA/L-endoglin mRNA target interactions based on total 
context score (Human ENG, NM_001114573, 3′-UTR length 670 nt) 
miRNA # of predict-ed MREs 
# of highly 
conserved 
MREs 
# of con-
served MREs 
in mice 
Total Context 
Score 
miR-1349/1389/378g 4 1 1 -0.62 
miR-762/4492/4498 2 0 0 -0.59 
miR-1587/3083/4505 3 0 1 -0.53 
miR-1915 2 1 0 -0.48 
miR-4649-5p 1 1 0 -0.46 
miR-608/1331/4651 1 1 0 -0.44 
miR-4486 3 0 0 -0.43 
miR-4690-5p 2 0 0 -0.39 
miR-1825 2 0 0 -0.39 
miR-4715-3p 1 0 0 -0.37 
miR-1976 2 1 1 -0.36 
miR-612/1285/3187-5p 3 0 0 -0.32 
miR-604 2 0 0 -0.31 
miR-1287 1 0 0 -0.31 
miR-4527 2 0 0 -0.30 
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Table 4: TargetScan identified miRNAs that are predicted to target MREs that are unique to the hu-
man S-endoglin mRNA isoform 
miRNA # of predict-ed MREs 
# of highly con-
served MREs 
# of conserved 
MREs in mice 
Total Con-
text Score 
miR-1607/1777b/3180-3p/3196 1 0 0 -0.26 
miR-4749-3p 1 0 0 -0.25 
miR-658 1 0 0 -0.24 
miR-3918 1 0 0 -0.15 
miR-920/4300 1 0 0 -0.13 
miR-3594-5p/4685-5p 1 0 0 -0.12 
miR-4257 1 0 1 -0.11 
miR-879/3188 1 0 0 -0.11 
miR-1909 1 1 0 -0.10 
miR-1193 1 0 0 -0.10 
miR-4435 1 0 0 -0.10 
miR-3192 1 0 0 -0.08 
miR-3691-5p 1 0 0 -0.06 
miR-3165 1 0 0 -0.04 
miR-677/4420 1 0 0 -0.03 
miR-1843-5p/4802-5p 1 0 0 N/A 
miR-1538/4745-3p 1 0 0 N/A 
miR-423a/423-5p/3184/3573-5p 1 0 0 N/A 
miR-4304 1 0 0 N/A 
miR-2417/4534 1 0 0 N/A 
 
Table 5: TargetScan identified miRNAs that are predicted to target MREs that interact with the unique 
and common 3′-UTR regions in human endoglin mRNA isoforms 
miRNAs Unique 3′-UTR  MREs 
Common 3’-
UTR MREs 
# of conserved 
MREs in Mice 
Total Context 
Score 
miR-1349/1389/378g 1 4 0 -0.73 
miR-296-5p 1 1 0 -0.51 
miR-4781-5p 1 1 0 -0.41 
miR-4437 1 2 0 -0.40 
miR-1669/4674 1 2 0 -0.37 
miR-486-3p 1 1 0 -0.30 
miR-1207-5p/4763-3p 1 1 0 -0.30 
 
ANALYSIS OF EXPERIMENTALLY 
SUPPORTED miRNA/mRNA  
TARGET DATA BASES:  
THE ENDOGLIN EXAMPLE 
Before one can develop “experimental 
hypotheses” to help guide research efforts 
regarding the validation of the specific miR-
NA/mRNA target interactions identified 
above, it is important to examine data sets of 
manually cataloged miRNA/mRNA interac-
tions which are supported experimentally 
(Figure 2) (Hsu et al., 2014; Sethupathy et 
al., 2006; Vergoulis et al., 2012; Vlachos et 
al., 2015; Xiao et al., 2009). The first availa-
ble database of experimentally supported 
miRNA/mRNA targets was DIANA-Tar-
Base (http://www.microrna.gr/tarbase) (Se-
thupathy et al., 2006). DIANA-TarBase v7.0 
was recently released and includes miR-
NA/mRNA interactions which have been 
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manually curated from information frag-
mented and buried in thousands of published 
studies and raw next-generation sequencing 
(NGS) data sets on 356 different cell types 
from 24 species (Vlachos et al., 2015).  
The curated data sets contain > 7,500 
miRNA/mRNA interactions obtained from 
“low yield” experimental techniques (e.g. re-
porter genes, Northern Blotting, qPCR, 
Western Blotting, ELISA, and 5′ RLM-
RACE) and > 500,000 interactions derived 
from high-throughput experiments (e.g. pSI-
LAC, CLIP-Seq/CLASH, Degradome-Seq, 
AGO-IP, biotin pull-down, miTRAP, 3′ Life, 
and IMPACTSeq) (Vlachos et al., 2015). At 
least two other similar databases, miRTar-
Base (http://mirtarbase.mbc.nctu.edu.tw/) 
(Hsu et al., 2014) and miRecords (http://mi-
records.umn.edu/miRecords/) (Xiao et al., 
2009), are also available. Notably however, 
these two databases have cataloged smaller 
sets of interactions, 51,460 and 2,705, re-
spectively. Given that DIANA-TarBase v7.0 
harbors significantly more entries than any 
other relevant database, we advocate for its 
use to survey experimentally supported 
miRNA/mRNA interactions. 
To investigate the curated data which 
support miRNA/endoglin mRNA target in-
teractions, the ‘‘ENG” gene symbol was en-
tered into the DIANA-TarBase v7.0 and all 
the cataloged interactions were identified. 
Table 7 documents ten human experimental-
ly supported miRNA/endoglin mRNA inter-
actions, and the methodology utilized to sub-
stantiate the interaction, the tissue and/or cell 
line used for experimentation, the location of 
the MRE if known, the type of interaction 
(direct or indirect), and the literature refer-
ence. Interestingly, three types of experi-
mental methodologies were utilized to con-
firm miRNA/endoglin mRNA interactions: 
pSILAC, HITS-CLIP, and IMPACT-Seq 
(Balakrishnan et al., 2014; Haecker et al., 
2012; Selbach et al., 2008; Tan et al., 2014) 
(Table 7). Briefly, pSILAC (pulsed stable
 
Table 6: Top 20 miRNA/endoglin mRNA target interactions predicted by both algorithms 
miRNA DIANA  (miTG Score) 
TargetScan  
(Total Context Score) 
miR-1349/1389/378g 0.858 -0.73 
miR-762/4492/4498 0.711 -0.59 
miR-4486 0.885 -0.40 
miR-4674 0.873 -0.37 
miR-4437 0.812 -0.40 
miR-612/1285/3187-5p 0.901 -0.30 
miR-1587-3083/4505 0.659 -0.53 
miR-4527 0.839 -0.28 
miR-296-5p 0.590 -0.51 
miR-876-3p 0.879 -0.21 
miR-1287 0.773 -0.30 
miR-326/330/330-5p 0.818 -0.20 
miR-1976 0.719 -0.28 
miR-342-5p/4664-5p 0.863 -0.13 
miR-4690-5p 0.667 -0.32 
miR-608/1331/4651 0.566 -0.38 
miR-4781-5p 0.532 -0.41 
miR-647 0.667 -0.25 
miR-1915 0.496 -0.42 
miR-486-3p 0.613 -0.30 
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Table 7: Experimentally supported human miRNA/endoglin mRNA interactions cataloged by DIANA-
TarBase 
miRNA Method Tissue Cell Line Location of MRE 
Type of In-
teraction Reference 
let-7b-5p pSILAC n/a HeLA Unknown Indirect Selbach et al., 2008 
miR-16-5p HITS-CLIP Umbilical Vein HUVEC Unknown Direct 
Balakrishnan et al., 
2014 
miR-20a-3p HITS-CLIP Umbilical Vein HUVEC Unknown Direct 
Balakrishnan et al., 
2014 
miR-23b-5p HITS-CLIP Umbilical Vein HUVEC Unknown Direct 
Balakrishnan et al., 
2014 
miR-29a-5p HITS-CLIP Umbilical Vein HUVEC Unknown Direct 
Balakrishnan et al., 
2014 
miR-103a-3p HITS-CLIP Umbilical Vein HUVEC Unknown Direct 
Balakrishnan et al., 
2014 
miR-107 HITS-CLIP Umbilical Vein HUVEC Unknown Direct 
Balakrishnan et al., 
2014 
miR-532-5p HITS-CLIP Bone Mar-row BCBLI Unknown Direct Haecker et al., 2012 
miR-628-5p HITS-CLIP Bone Mar-row HMSC Unknown Direct 
Balakrishnan et al., 
2014 
miR-522-3p IMPACT-Seq 
Mammary 
Gland MDAM468 5′-UTR Direct Tan et al., 2014 
 
isotope labelling with amino acids in cell 
culture) methodology involves the transfec-
tion of a given miRNA mimic into a cell line 
of choice that have been isotopically labeled 
or non-labeled and followed by mass-
spectrometry-based proteomics to measure 
changes in protein production (Selbach et al., 
2008). pSILAC does not establish whether 
the reduction in a given protein results from 
the miRNA directly binding to a MRE har-
bored within an mRNA of interest (Selbach 
et al., 2008). In contrast, the HITS-CLIP 
(high-throughput sequencing of RNA isolat-
ed by crosslinking immunoprecipitation) ex-
perimental approach involves the transfec-
tion of a given miRNA mimic into a cell line 
of choice followed by ultraviolet (UV) cross-
linking to generate AGO/miRNA/RNA 
cross-linked regions (see Figure 1). The 
cross-linked RNAs are subsequently im-
munoprecipitated (IP) with AGO specific an-
tibodies, the RNA is then extracted and sub-
jected to high-throughput NGS (Balakrish-
nan et al., 2014; Haecker et al., 2012). Im-
portantly, HITS-CLIP can identify direct 
miRNA/mRNA interactions. However, it is 
more difficult to pinpoint MRE locations lo-
cated within the “pulled down” mRNA (Ba-
lakrishnan et al., 2014; Haecker et al., 2012) 
when compared to the IMPACT-Seq (identi-
fication of MREs by pull-down and align-
ment of captive transcripts-sequencing) 
methodology described below. The, IM-
PACT-Seq procedure involves the transfec-
tion of a given biotinylated miRNA mimic 
into a cell line of choice. MiRNA/mRNA 
targets are then pulled down utilizing strep-
tavidin. The product is subsequently treated 
with RNase, and MREs are then identified 
by NGS of RNase-resistant fragments (Tan 
et al., 2014). This experimental method not 
only results in the direct identification of 
miRNA/mRNA targets but also leads to the 
characterization of MRE(s) located within 
the targeted mRNA (Tan et al., 2014).  
Cataloged results using pSILAC indicat-
ed that let-7b-5p decreased endoglin expres-
sion (Table 7, Selbach et al., 2008); yet nei-
ther Diana-microT-CDS nor TargetScan 
analysis of human endoglin mRNAs identi-
fied let-7b-5p MREs (not shown). These re-
sults suggest that let-7b-5p may not directly 
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bind with specific MRE(s) harbored within 
this mRNA. Rather, this analysis supports 
the hypothesis that let-7b-5p indirectly de-
creases human endoglin expression. There-
fore, to investigate whether endoglin expres-
sion is directly or indirectly regulated by this 
miRNA, the human S-endoglin mRNA iso-
form was manually screened for putative let-
7b-5p MREs. Although let-7b-5p MREs 
were not located in the 3′-UTR, two putative 
CDS let-7b-5p MREs were identified 884 nts 
(5′ ACCUCA 3′, 6mer “seed” region) and 
1361 nts (5′ CUACCUCA 3′, 8mer “seed” 
region) downstream from the start codon. It 
is not clear why the Diana-microT-CDS al-
gorithm did not identify the putative let-7b-
5p binding sites harbored in the CDS of this 
mRNA isoform. Hence, the complementary 
use of manual screening for putative MREs 
remains a viable strategy for hypothesis de-
velopment and subsequent experimental de-
signs.  
Nine miRNA/human endoglin mRNA 
target sites (Table 7) were identified by tech-
niques (HITS-CLIP and IMPACT-Seq) that 
require the direct interaction of these miR-
NAs with the detected mRNA. Hence, spe-
cific MRE sequence(s) must be identifiable 
within endoglin mRNAs (Balakrishnan et al., 
2014; Haecker et al., 2012). It was surpris-
ing, therefore, that only two out of nine 
miRNAs from Table 7 (miR-16-5p and miR-
628-5p) were predicted to interact with hu-
man endoglin mRNAs by the Diana-microT-
CDS algorithm. This algorithm computed 
that the human S-endoglin mRNA isoform 
harbors three miR-16-5p MREs, one site was 
identified (5′ GCUGCU 3′, 6mer “seed” re-
gion) in the 3′-UTR, 842 nts downstream 
from the stop codon and two additional sites 
were identified in the CDS (5′ UGCUGCU 
3′, 7mer “seed” region), 34 and 473 nts 
downstream from the start codon. Addition-
ally, this mRNA isoform was predicted to 
have three miR-628-5p MREs, two sites 
were identified (5′ CAGCAU 3′, 6mer 
“seed” region) in the 3′-UTR, 184 and 223 
nts downstream from the stop codon (within 
the intron 14 sequence) and one additional 
site was identified in the CDS (5′ 
UGUCAGCA 3′, 8mer “seed” region), 1645 
nts downstream from the start codon. Inter-
estingly, the human L-endoglin mRNA 
would not include the two miR-628-5p 
MREs harbored in the 3′-UTR because this 
mRNA isoform does not harbor intron 14. In 
contrast to results from the Diana-microT-
CDS algorithm, TargetScan did not predict 
any of the ten miRNAs identified to interact 
with human endoglin mRNAs (Table 7), in-
cluding the 3′-UTR miR-16-5p or miR-628-
5p MRE.  
Although neither algorithm identified 
human endoglin mRNA MRE target sites for 
HITS-CLIP validated miRNAs (miR-20a-3p, 
miR-23b-5p, miR-29a-5p, miR-103-3p, miR-
107, and miR-532-5p) (Table 7), human en-
doglin mRNAs were manually screened for 
these putative miRNA binding sites given 
the failure rate of prediction algorithms 
(Reczko et al., 2012). When the human S-
endoglin mRNA isoform was subjected to 
manual sequence analysis two putative miR-
20a-3p CDS MREs (5′ AUGCAG 3′, 6mer 
“seed” region) were located (804 and 1239 
nts downstream from the start codon) and 
two potential miR-23b-5p MREs (5′ 
AACCCA 3′, 6mer “seed” region) were 
identified in the 3′-UTR (448 and 509 nts 
downstream from the stop codon) of this 
mRNA isoform. Additionally, a miR-29a-5p 
MRE (5′ AAAUCAG 3′, 7mer “seed” re-
gion) was detected in the human S-endoglin 
mRNA 3′-UTR (882 nt downstream from the 
stop codon). It was also observed that two 
putative miR-532-5p CDS MREs (5′ AG-
GCAU 3′ and 5′ GGCAUG 3′, 6mer “seed” 
regions) located 247 and 1236 nts down-
stream from the start codon. Finally, se-
quence analysis detected three identical miR-
103-3p and miR-107 MREs harbored in the 
human S-endoglin mRNA which overlaped 
with the three Diana-microT-CDS algorithm 
predicted miR-16-5p MREs above (3′-UTR 
MRE [5′ GCUGCU 3′, 6mer “seed” region] 
842 nts downstream from the stop codon and 
two CDS MREs [5′ UGCUGCU 3′, 7mer 
“seed” region] 34 and 473 nts downstream 
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from the start codon).  It is now clear that 
miR-16-5p, miR-103-3p, and miR-107 be-
long to a group of paralogous, evolutionari-
ly-conserved miRNAs termed the miR-
15/107 family (Finnerty et al., 2010). The 
miR-15/107 family includes miR-15a-5p, 
miR-15b-5p, miR-16-5p, miR-103-3p, miR-
107 (which are expressed in all vertebrates), 
miR-195-5p, miR-424-5p, miR-497-5p, 
miR-503-5p (which are expressed in mam-
mals), and miR-646 (human specific) (Fin-
nerty et al., 2010). Importantly this group of 
miRNAs shares a sequence (5′ AGCAGC 3′) 
near the 5′ end that complements with the 
Diana-microT-CDS algorithm predicted 
miR-16-5p MREs (5′ GCUGCU 3′) and the 
manually identified miR-103-3p and miR-
107 MREs within the human S-endoglin 
mRNA. Therefore, we hypothesize that some 
or all of the miR-15/107 family members 
may regulate endoglin expression. Again, it 
is not clear why the Diana-microT-CDS and 
TargetScan algorithms did not identify the 
miR-20a-3p, miR-23b-5p, miR-29a-5p, miR-
103-3p, miR-107 and miR-532-5p MREs in 
human S-endoglin mRNA that were detected 
manually. 
The IMPACT-Seq technique was utilized 
to experimentally demonstrate that miR-522-
3p can regulate human endoglin expression 
and that the MRE for this miRNA was local-
ized to the 5′-UTR region of human endoglin 
mRNA isoforms (Tan et al., 2014) (Table 7). 
These investigators found that miR-522-3p 
typically interacts with noncanonical MRE 
sequences which contain motifs partially 
complementary to both the 5′ and 3′ ends of 
this miRNA. Therefore, the human S-
endoglin mRNA was manually screened for 
the miR-522-3p MRE. The proposed interac-
tion site (5′ CUUCUCUAAGGAAGCG-
CAUUUC 3′, the partially complementary 
motifs are underlined) was identified 40 nts 
downstream from the transcription initiation 
start site. Given that this predicted MRE is 
harbored in the 5′-UTR region of the human 
endoglin mRNA isoforms, miR-522-
3p/endoglin mRNA interactions would not 
be identified by the target algorithms dis-
cussed above since they are not programmed 
to analyze this region. Furthermore, with the 
tendency of miR-522-3p to interact with 
noncanonical MRE sequences, Tan et al. 
(2014) demonstrated that of the 2,467 3′-
UTR miR-522-3p MREs that they identified 
only 111 were predicted by target algo-
rithms.  
In conclusion, it is important to note that 
although only two of the ten DIANA-
TarBase v7.0 cataloged experimentally iden-
tified miRNA/human endoglin mRNA inter-
actions (Table 7) (Selbach et al., 2008; Bala-
krishnan et al., 2014; Haecker et al., 2012; 
Tan et al., 2014) were predicted by miRNA 
target algorithms, manual sequence inspec-
tion detected potential binding sites for all of 
these miRNAs. Given that the functional im-
portance of the putative MRE(s) for each 
miRNA described above has not been veri-
fied, the biological relevance of each site can 
be experimentally validated by fulfilling four 
well-defined experimental criteria defined 
below. Since the miRNA/human endoglin 
mRNA interactions have already been exper-
imentally supported (Table 7), there is less 
concern for wasted time and resources test-
ing “false positive” miRNA/mRNA predict-
ed targets (Vlachos and Hatzigeorgiou, 
2013). 
 
ANALYSIS OF THE PUBLISHED  
LITERATURE: THE ENDOGLIN  
EXAMPLE REVISITED 
For this review article we subjected the 
human endoglin mRNA to Diana-microT-
CDS and TargetScan miRNA target analyses 
and examined DIANA-TarBase v7.0 data 
sets of cataloged and published experimen-
tally supported miRNA/human endoglin 
mRNA interactions (see above). Given that 
the majority of the identification and catalog-
ing of miRNA/mRNA target interactions by 
DIANA-TarBase v7.0 result from high-
throughput techniques (Vlachos et al., 2015) 
without further functional analyses, it is im-
portant to examine the published literature to 
determine that a mRNA of interest is regu-
lated by identified miRNAs (low-yield tech-
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niques). In addition, literature may reveal 
whether miRNAs identified by target algo-
rithm searches and DIANA-TarBase v7.0 
have been demonstrated to regulate other 
mRNA targets (Figure 2). Manually curating 
this data will serve as an important addition-
al step in allowing the investigator to devel-
op the most biologically compelling “exper-
imental hypotheses”. 
In our test case, the key words “en-
doglin” and “miRNAs” were evaluated by 
PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed). Six 
publications were identified (Table 8). None 
of these publications were curated by DI-
ANA-TarBase v7.0. Yoo et al., (2011, 2012) 
cloned and characterized two novel miRNAs 
from human embryonic stem cells that were 
designated miR-5739 and miR-6087. These 
investigators demonstrated that the human S-
endoglin mRNA isoform harbored a func-
tional miR-5739 and miR-6087 3′-UTR 
MRE (5′ GCUCUCCG 3′ and 5′ 
CCCGCCUC 3′, 8mer “seed” regions) locat-
ed 348 and 366 nts downstream from the 
stop codon of this mRNA isoform (Yoo et 
al., 2011, 2012). Although both miRNAs 
have been annotated (miRBase Release 21, 
accession #: MI0019412 and MI0020364), 
DIANA-microT-CDS and TargetScan did 
not predict miR-5739/human endoglin and 
miR-6087/human endoglin mRNA target in-
teractions since these miRNAs have yet to be 
included in these algorithms (Garcia et al., 
2011; Paraskevopoulou et al., 2013; Reczko 
et al., 2012). 
Shyu et al. (2013) demonstrated that me-
chanical stretch and TGFβ1 increased miR-
208a-5p and endoglin mRNA and protein 
expression in rat cardiac myoblasts (Table 
8). This same laboratory also established that 
miR-208a-5p and endoglin expression was 
up-regulated in an in vivo volume overload-
induced heart failure rat model (Wang et al., 
2014) (Table 8). Importantly, several recent 
studies have shown that, in addition to tar-
geting mRNAs for translational repression 
and/or destabilization by the miRISC, miR-
NAs may also function to induce gene ex-
pression by direct interactions with MRE se-
quences harbored within active promoters or 
by triplex structure formation (double-
stranded DNA/RNA) stabilized by AGO2 
(Dharap et al., 2013; Ma et al., 2010; Majid 
et al., 2010; Place et al., 2008; Toscano-
Garibay et al., 2014; Zhang et al., 2014). 
Shyu et al. (2013) speculate that miR-208a-
5p may interact with a MRE located in the 
promoter region of the rat Eng gene, which 
in turn induces rat endoglin gene expression. 
Unfortunately, the predicted rat Eng promot-
er MRE does not show significant comple-
mentarity to miR-208a-5p and does not fol-
low seed sequence rules. These authors have 
yet to test the biological activity of this site 
 
Table 8: AlI published studies investigating miRNA/endoglin regulation 
miRNAs Method Tissue Cell Line Location of MRE Reference 
miR-5739 reporter, Western, qPCR n/a HUVEC 1 x 3′-UTR Yoo et al., 2011 
miR-6087 reporter, Western, qPCR n/a HeLa 1 x 3′-UTR Yoo et al., 2012 
miR-208a-5p n/a heart H9c2 n/a Shyu et al., 2013 
miR-208a-5p n/a heart n/a n/a Wang et al., 2014 
miR-15 family 
reporter, Westerns, gain 
of fuction, loss of func-
tion, in vivo 
heart mice 
cardiac 
fibroblasts 
myocytes 
1 x 3′-UTR Tijsen et al., 2014 
miR-370-3p reporter, Westerns, gain of function, xenograft ovary 
IGROVI 
TOV112D 1 x 3′-UTR Chen et al., 2014 
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(Shyu et al., 2013). Therefore, it is possible 
that the elevated endoglin levels could be the 
result of secondary regulatory events (i.e. 
down-regulation of a miR208a target that re-
sults in elevated endoglin expression). Addi-
tionally, mouse endoglin mRNAs harbor a 
miR-208a-5p MRE located within the 3′-
UTR that was predicted by Diana-microT-
CDS (0.517 miTG score). This site is con-
served in rats but not in humans. Given that 
translational up-regulation by miRNAs has 
also been observed as a result of the direct 
action of miRNAs (reviewed in Valinezhad 
Orang et al., 2014; Vasudevan, 2012), it is 
possible that miR-208a-5p binding to this 
predicted MRE results in the detected up-
regulation of rat endoglin. Taken together it 
is clear that more studies are needed to de-
termine the mechanism by which miR-208a-
5p regulates rat endoglin gene expression 
and to investigate whether this mechanism is 
also employed in regulating human ENG 
gene expression. 
miRNA profiling expression experiments 
utilizing ovarian cancer cells and ovarian 
cancer clinical samples demonstrated that a 
number of miRNAs were aberrantly ex-
pressed, including miR-370-3p, which was 
down-regulated in these studies (Iorio et al., 
2007; Lee et al., 2012a). Given that endoglin 
is known to be over-expressed in some can-
cers (Rosen et al., 2014), Chen et al. (2014) 
analyzed the human endoglin mRNA for the 
presence of miR-370-3p MRE(s) sequences 
by the TargetScan algorithm (Table 8). A 
miR-370-3p 3′-UTR MRE (5′ CCAGCAGG 
3′, 8mer “seed” region, -0.21 total context 
score) was predicted 256 nts downstream 
from the stop codon of the human S-
endoglin mRNA isoform (Chen et al., 2014). 
After identifying this MRE, Chen et al. 
(2014) subsequently demonstrated that hu-
man endoglin was negatively regulated by 
miR-370-3p directly interacting with this se-
quence (Table 8). We also surveyed the 259 
Diana-microT-CDS predicted human S-
endoglin MRE sequences and found that this 
algorithm also predicted the same miR-370-
3p 3′-UTR MRE (0.519 miTG score) interac-
tion site. However, this algorithm identified 
one additional miR-370-3p 3′-UTR MRE (5′ 
CCCCAGCAAGC 3′, 8mer “seed” + mis-
match region, underlined) and the potential 
functionality of this site has not been tested. 
Many research studies have revealed that 
miRNAs are important regulators of cardiac 
development and play essential roles in car-
diovascular diseases (reviewed in Small et 
al., 2010). Importantly, miRNA expression 
profiling experiments have identified a sub-
set of miRNAs expressed in the normal heart 
and which are modulated during cardiovas-
cular disease, including the miR-15/107 fam-
ily described above (Hullinger et al., 2012; 
Nigam et al., 2010; Porrello et al., 2011, 
2013; van Rooij et al., 2006; Zampetaki et 
al., 2014).  
Tijsen et al. (2014) (Table 8) focused 
their attention on the miR-15/107 family 
since some members are expressed in both 
cardiomyocytes and fibroblasts (Hullinger et 
al., 2012). Mouse TargetScan analysis pre-
dicted miR-15/107 family 3′-UTR MREs in 
canonical TGFβ (TGFβR1, TGFβR2, 
TGFβR3, endoglin, SMAD2, SMAD3, 
SMAD4, SMAD7), and in non-canonical 
TGFβ (TGFβR1, TGFβR2, TRAF6, TAK1, 
p38) signaling pathways (Tijsen et al., 2014). 
Notably, mouse endoglin mRNA was pre-
dicted to harbor a miR-15/107 family 3′-
UTR MRE (5′ UGCUGCU 3′, 7mer “seed” 
region, -0.18 total context score) located 442 
nts downstream from the stop codon. Lucif-
erase reporter assays suggest direct targeting 
of these miRNAs within the mouse endoglin 
3′-UTR (Tijsen et al., 2014) (Table 8). Tijsen 
et al. (2014) also demonstrated that when 
mice were injected subcutaneously with 
locked nucleic acid (LNA)-based antimiR-
15b, the loss of the miR-15 family members 
(miR-15-5p, miR-16-5p, miR-195-5p, miR-
322 (mouse homolog to human miR-424-
5p), and miR-497-5p resulted in a significant 
up-regulation of TGFβR1 and SMAD3 
mRNA, and a trend towards up-regulation of 
p38, TGFβR2, TGFβR3, SMAD4, SMAD7, 
and endoglin mRNA. Additionally, when rat 
neonatal cardiomyocytes were transfected 
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with miR-15b mimics, the overexpression of 
this miRNA resulted in decreased mRNA 
levels of p38, SMAD2, SMAD3, and en-
doglin (Tijsen et al., 2014). Taken together, 
these investigators concluded that the miR-
15/107 family is a novel regulator of cardiac 
hypertrophy and fibrosis through the inhibi-
tion of the TGFβ-signaling pathway (Tijsen 
et al., 2014).  
Again, it is important to note that the 
miR-15/107 family members, miR-16-5p, 
miR-103a-3p, and miR-107 were identified 
to interact with human endoglin mRNAs by 
the HITS-CLIP technique (Table 7) (Bala-
krishnan et al., 2014). Additionally, the Di-
ana-microT-CDS algorithm predicted that 
human S-endoglin mRNAs harbor three 
miR-16-5p MREs, one 3′-UTR and two CDS 
interaction sites (Table 7, and see discussion 
above). Interestingly, Tijsen et al. (2014) on-
ly utilized TargetScan to interrogate the hu-
man, mouse, and rat endoglin mRNAs and 
came to the conclusion that only mouse en-
doglin mRNAs harbor a miR-15/107 family 
MRE. Therefore, their data regarding the de-
creased endoglin mRNA expression in miR-
15b mimic transfected rat neonatal cardio-
myocytes (Tijsen et al., 2014) is confusing 
given that the miR-15/107 family 3′-UTR 
MRE is not conserved in rat endoglin 
mRNA. This observation prompted us to in-
vestigate whether the Diana-microT-CDS al-
gorithm would identify putative miR-15/107 
family 3′-UTR MREs harbored in the mouse 
and/or rat endoglin mRNAs. This algorithm 
predicted the same MRE sequence (0.510 
miTG score) within mouse endoglin mRNA 
as TargetScan. However, Diana-microT-
CDS found that this site was conserved in rat 
endoglin mRNAs and actually predicted an 
additional miR-15/107 family 3′-UTR MRE 
within mouse endoglin mRNAs (5′ 
UGCUGCU 3′, 7mer “seed” region) located 
864 nts downstream from the stop codon. 
Although Tijsen et al. (2014) demon-
strated that multiple miR-15/107 family 
members, including miR-16-5p, were up-
regulated in human diseased heart samples 
they did not investigate whether or not en-
doglin mRNA and/or protein levels were re-
duced in these samples, especially since their 
TargetScan analyses suggested that human 
endoglin would not be regulated by this 
miRNA family. This was an important over-
sight given that, like mouse and rat endoglin 
mRNAs, human endoglin mRNA isoforms 
harbor algorithm-identified miR-15/107 fam-
ily MREs and therefore may also be regulat-
ed by miR-15/107 family members. Taken 
together, our endoglin case study clearly 
demonstrates the importance of utilizing 
multiple target algorithms and the data curat-
ed by DIANA-TarBase v7.0, in conjunction 
with the published literature in order to ap-
propriately interpret miRNA data. 
Given that endoglin has been established 
to play a regulatory role in TGFβ signaling 
(reviewed in Kapur et al., 2013; López-
Novoa and Bernabeu, 2010; Nachtigal et al., 
2012; Rosen et al., 2014), and since aberrant 
TGFβ signaling can play a role angiogenesis, 
atherosclerosis, atrial fibrillation, cancer, di-
abetes mellitus, heart failure, hereditary 
hemorrhagic telangiectasia (HHT), myocar-
dial infarction, pre-eclampsia, and pulmo-
nary hypertension (Kapur et al., 2013; 
López-Novoa and Bernabeu, 2010; Nacht-
igal et al., 2012; Rosen et al., 2014), it fol-
lows that one should also examine the pub-
lished literature to investigate whether or not 
any of the algorithm computed miRNAs 
(259 Diana-microT-CDS [Table 1], 152 Tar-
getScan miRNA/miRNA families [Table 2]) 
and the experimentally cataloged miRNAs 
(Table 7) predicted to interact with human 
endgolin mRNAs, have been shown to play a 
role in any of the pathologies described 
above. Therefore, each identified miRNA 
was utilized as a key word and interrogated 
by PubMed. miRNA searches that resulted in 
over forty “hits” were re-analyzed utilizing 
the given miRNA and the listed pathologies 
described above.  
Importantly, members of the miR-15/107 
family have been demonstrated to play key 
roles in gene regulation involved in cell divi-
sion, metabolism, stress response, and angi-
ogenesis (reviewed in Finnerty et al., 2010). 
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This family has also been implicated in 
pathological processes including cancers, 
cardiovascular disease and neurodegenera-
tive diseases (Finnerty et al., 2010). Addi-
tional miRNAs with potential roles in regu-
lating endoglin biology include miR-628-5p 
(Table 6) given that it is down-regulated in 
prostate cancer (Srivastava et al., 2014) and 
the miR-15/107 family and miR-628-5p that 
are regulated by IL-3, GM-CSF and G-CSF 
in acute myeloid leukemia (Favreau et al., 
2012). Further, let-7b-5p, miR-20a, and 
miR-29a-5p (experimentally cataloged 
miRNAs which target human endoglin 
mRNAs, Table 7) are potent tumor suppres-
sors which are involved in cell proliferation, 
cell cycle regulation, and have been associat-
ed with increased tumor metastasis (Fabbri et 
al., 2007; Pickering et al., 2009; Yun et al., 
2011). In contrast, miR-23b-5p, miR-522-3p, 
and miR-532-5p (experimentally cataloged 
miRNAs which target human endoglin 
mRNAs, Table 7) appear to have metastatic-
promoting functions (Ell et al., 2014; Kitago 
et al., 2009; Tan et al., 2014). Finally, sever-
al human endoglin mRNA algorithm com-
puted interacting miRNAs that might be in-
teresting to investigate include miR-26a/b-
5p, miR-93-5p, miR-150-5p, miR-326, miR-
370 given that these miRNAs have been 
shown to have tumor suppressor/promoter 
and cardiovascular roles (Chen et al., 2014; 
Fang et al., 2011; Icli et al., 2014; Ito et al., 
2014; Kim et al., 2014; Lo et al., 2012; Lyu 
et al., 2014; Zeitels et al., 2014). 
 
DEVELOP EXPERIMENTAL  
HYPOTHESES: THE CONTINUED 
EDOGLIN CASE STUDY 
Once the plethora of information from 
prediction algorithms, published validations 
of miRNA/mRNA interactions, and manual 
sequence inspections of miRNA binding 
sites has been assembled, prioritization of 
specific miRNA/mRNA target interactions to 
investigate can more effectively proceed. 
Among the number of putative miR-
NA/human endoglin mRNA interactions 
documented above, the remainder of this re-
view article will focus on miR-370 (Table 8) 
since this miRNA has already been identified 
and validated to interact with endoglin 
mRNA and negatively regulate endoglin pro-
tein expression (Chen et al., 2014). We will 
utilize this published example to outline and 
explain the four criteria/experimental proce-
dures to thoroughly validate a miRNA/ 
mRNA target interaction as biologically sig-
nificant.  
 
VALIDATION OF miRNA/mRNA  
INTERACTIONS 
Demonstrate miRNA and target mRNA co-
expression in vivo 
Clearly a given miRNA and its target 
mRNA must be co-expressed in order for the 
miRNA to regulate the expression of a given 
biological target. Therefore, miRNA and tar-
get mRNA co-expression experimental stud-
ies should be performed first (Figure 2), 
since there is no need to proceed with addi-
tional validation experiments if a tissue or 
cell type can’t be identified where they are 
co-expressed.  
Co-expression is typically demonstrated 
by simply performing Northern blot analysis 
or quantitative real-time PCR (qPCR) using 
total RNA isolated from a specific cell type 
or tissue, and probes or primers specific for a 
given miRNA and mRNA target (Sansom et 
al., 2011). We recommend that qPCR exper-
iments be performed given that many com-
mercial assays are available to measure both 
miRNA (Life Technologies, Exiqon, Qiagen) 
and mRNA (Life Technologies, Qiagen) lev-
els from many species and due to the ease 
and reproducibility of these assays. 
If expression data regarding the miRNA 
and/or target mRNA of interest is scarce, 
then many tissues and/or cell lines may need 
to be screened (Sansom et al., 2010). Addi-
tionally, if cell specific expression infor-
mation concerning the miRNA and/or target 
mRNA of interest is unknown, then it may 
also beneficial to perform miRNA and 
mRNA in situ hybridization and immuno-
histochemical experiments utilizing paraffin-
embedded, formalin-fixed tissues to address 
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the question of co-expression (Nuovo, 2010; 
Sansom et al., 2010). 
As described in the “Analysis of the Pub-
lished Literature” section above (Table 8), 
recent reports suggest that miR-370 is a tu-
mor suppressor (An et al., 2012; Iorio et al., 
2007; Lee et al., 2012a; Zhang et al., 2012). 
Given that angiogenesis is required for the 
survival and growth of solid cancers (re-
viewed in Carmeliet, 2003) and since en-
doglin is essential for angiogenesis (Dallas et 
al., 2008), Chen et al. (2014) investigated 
whether human endoglin mRNAs harbored 
putative miR-370 MREs by utilizing the 
TargetScan algorithm. A miR-370-3p 3′-
UTR MRE (5′ CCAGCAGG 3′, 8mer “seed” 
region) was predicted 256 nts downstream 
from the stop codon in the human S-endoglin 
mRNA isoform (Chen et al., 2014). It is im-
portant to note that of the 249 miRNA MRE 
sites predicted by TargetScan in the human 
S-endoglin mRNA isoform, miR-370-3p had 
only the 40th highest total context score  
(-0.21). Thus, the decision by these investi-
gators to test the hypothesis that miR-370-3p 
can regulate endoglin expression was based 
on the published observations that this miR-
NA target might be biologically relevant 
even though the context score for miR-370-
3p was not that striking (Table 2). 
Importantly, Chen et al. (2014) initiated 
their study by investigating whether or not 
human ovarian cancer tissues and endome-
trioid ovarian cancer cell lines expressed en-
doglin and miR-370-3p. Northern blot and 
qPCR experiments demonstrated that, com-
pared with normal ovarian tissues and con-
trol ovarian epithelial cells, miR-370-3p ex-
pression levels were attenuated in endome-
trial ovarian cancer tissues and in two endo-
metrioid ovarian cancer cell lines (IGROV1 
and TOV112D) (Chen et al., 2014). Addi-
tionally, these investigators utilized im-
munohistochemical and Western blot exper-
iments to demonstrate that endoglin was ex-
pressed in normal ovarian tissue and in 
IGROV1 and TOV112D cells (Chen et al., 
2014). Taken together, these data indicated 
that miR-370-3p and endoglin were co-
expressed in ovarian tissues and cells. Fur-
ther evaluation of the biological importance 
of the miR-370-3p MRE harbored in the 
human S-endoglin mRNA isoform is war-
ranted. 
 
Demonstrate interaction of miRNA to a 
specific MRE target site 
After the demonstration of co-expression 
of the miRNA and target mRNA of interest, 
the physical interaction of a specific miRNA 
with a candidate MRE harbored in a target 
mRNA needs to be confirmed (Figure 2). 
The majority of MRE validation studies em-
ploy co-transfection experiments using chi-
meric luciferase reporter plasmid constructs 
which harbor a wild-type or mutated MRE of 
interest and reagents that either up-regulate 
(i.e., gain-of-function) or inhibit miRNA ac-
tivity (i.e., loss-of-function) to rapidly, relia-
bly, and quantitatively screen MRE target-
sites (Nicolas et al., 2011; Sansom et al., 
2010). The rationale for performing these 
types of experiments is based on the princi-
ple that if a given mRNA is a true target of a 
specific miRNA, then manipulation of en-
dogenous miRNA concentrations should cor-
respond to predictable changes in target pro-
tein levels (i.e. luciferase reporter lev-
els/activity) (Sansom et al., 2010).  
For construction of chimeric luciferase 
reporter constructs, the predicted MRE se-
quence from the target gene, most often lo-
cated in the 3’-UTR but also in the 5’-UTR 
and CDS see (Akhtar et al., 2015; Zhou and 
Rigoutsos, 2014), is cloned immediately 
downstream of the luciferase (Photinus or 
Renilla) open reading frame sequence con-
tained in the reporter plasmid (Nicolas et al., 
2011; Sansom et al., 2010). If possible, it is 
important that the entire 3′-UTR be included 
since a truncated version of this sequence 
may provide inappropriate accessibility to a 
given miRNA. Additionally, by sub-cloning 
the entire 3′-UTR of the target gene of inter-
est, a single reporter construct can be utilized 
to investigate most of the algorithm-
predicted miRNA/mRNA binding sites. For 
many human and rodent target mRNAs, 
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chimeric luciferase reporter constructs con-
taining the entire 3′-UTR can be obtained 
from several commercial sources (e.g., Gen-
eCopoeia, Inc; OriGene Technologies, Inc; 
SwitchGear Genomics). We recommend the 
utilization of a dual-reporter vector system 
(e.g., psiCHECK-2, Promega; pEZX-MT05, 
pEZX-MT06, GeneCopoeia, Inc) since this 
enables transfection normalization for accu-
rate across-sample comparison by transfect-
ing a single plasmid (Sansom et al., 2010).  
Once the wild-type and mutant MRE 
chimeric luciferase reporter constructs have 
been generated, consideration must be given 
to augmentation or attenuation of the cellular 
levels of a given mature miRNA. Briefly, 
miRNA mimics, which are utilized for gain-
of-function experiments, are chemically syn-
thesized as double-stranded RNA oligonu-
cleotides which simulate the Dicer cleavage 
product (Figure 1) after transfection into 
cells. These transfected mimics are subse-
quently processed into mature miRNAs 
(guide strand) such that the passenger strand 
(antisense to the guide strand) is excluded 
through a proprietary chemical modification 
pattern (commercially available from Ambi-
on/Life Technologies, Dharmacon, Qiagen). 
Alternatively, miRNA mimics can be syn-
thesized in three strands (Bramsen et al, 
2007) rather than the two strand mimics de-
scribed above. These mimics are comprised 
of a mature miRNA (guide strand) that is a 
chemically synthesized unmodified RNA ol-
igonucleotide strand with a sequence corre-
sponding exactly to the annotation in miR-
Base (http://www.mirbase.org) and a pas-
senger strand that is split in two separate an-
tisense chemically synthesized LNA modi-
fied RNA oligonucleotide strands (commer-
cially available from Exiqon). After transfec-
tion into cells, the segmented nature of the 
passenger strand ensures that only the mature 
miRNA (guide strand) is loaded into the 
RISC with no resulting miRNA activity from 
the passenger strand. Regardless of the 
chemical makeup of the mimic utilized, 
transfection of a miRNA mimic into cells 
will increase the proportion of RISC contain-
ing this particular miRNA and therefore, 
gain-of-function studies can assess the bio-
logical consequences (i.e. repression of lu-
ciferase reporter levels/activity) resulting 
from an increase in the activity of the mim-
icked miRNA (Sansom et al., 2010).  
In contrast, miRNA inhibitors, which are 
utilized for loss-of-function experiments, are 
chemically synthesized, single-stranded, 
modified antisense RNA oligonucleotides 
which are designed to bind with and form 
highly stable heteroduplexes with the com-
plementary endogenous miRNAs when in-
troduced into cells (Meister et al., 2004; San-
som et al., 2010). As a consequence, the 
formation of heteroduplexes effectively pre-
vents this miRNA from hybridizing with its 
normal cellular mRNA targets. Therefore, 
loss-of-function studies can assess the bio-
logical consequences (i.e. de-repression of 
luciferase reporter levels/activity) due to a 
decrease in the activity of a selected miRNA 
(Sansom et al., 2010).  
Despite widespread use of chimeric lu-
ciferase reporter genes, miRNA gain-of-
function experiments can result in mislead-
ing assessment of targets since transient 
transfection of miRNA mimics generally re-
sults in supra-physiological concentrations of 
miRNAs that may potentially generate false 
positive results (Arvey et al., 2010; Bracken 
et al., 2008). For example, exaggerated 
miRNA over-expression can potentially satu-
rate miRISC complexes and displace other 
endogenous miRNAs and consequently 
cause low affinity target sites to appear func-
tionally important (Khan et al., 2009). There-
fore, it is important that miRNA gain-of-
function transfection experiments be opti-
mized to deliver the minimal required 
mRNA mimic concentration for validation of 
a biological effect. Additionally, the appro-
priate negative and positive control experi-
ments need to be performed to ensure that 
the resulting change in luciferase activity is 
due to the increased activity of the mimicked 
miRNA. For example, negative control chi-
meric luciferase reporter transfection exper-
iments should always be performed utilizing 
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scrambled miRNA mimics to demonstrate 
the specificity of a given miRNA for a MRE 
localized in the mRNA target of interest 
(Sansom et al., 2010). Finally, miRNA over-
expression experiments are often performed 
in a cell environment that is artificial to the 
chosen miRNA. However, due to tissue-
specific miRNA biogenesis and binding 
(Kedde et al., 2007; Siomi and Siomi, 2010), 
these studies should be ideally performed in 
relevant cell lines that express the investigat-
ed miRNA and the mRNA of interest. 
For the endoglin case study, to investi-
gate miR-370-3p interaction with the pre-
dicted MRE site harbored in the 3′-UTR of 
human endoglin mRNA, Chen et al. (2014) 
engineered two chimeric luciferase/endoglin 
reporter gene constructs. The wild-type chi-
meric construct harbored a small portion of 
the human endoglin 3′-UTR (29 nts) includ-
ing the miR-370-3p MRE and an identical 
chimeric construct in which the miR-370-3p 
MRE seed sequence was mutated. The two 
human endometrioid ovarian cancer cell 
lines described above were individually 
transfected with these reporter constructs and 
miR-370-3p mimics and luciferase activity 
was measured. Cells transfected with the 
wild-type chimeric luciferase/endoglin re-
porter construct and miR-370-3p mimic ex-
hibited the lowest luciferase activity (Chen et 
al., 2014). In contrast, the luciferase activity 
was unchanged in cells transfected with the 
mutant chimeric luciferase/endoglin reporter 
construct and miR-370-3p mimics. Since the 
transfected ovarian cancer cells endogenous-
ly express miR-370-3p, these investigators 
also performed identical luciferase reporter 
transfection experiments utilizing a miR-
370-3p inhibitor. Notably, these transfection 
experiments demonstrated that luciferase re-
porter activity was increased in cells trans-
fected with the wild-type chimeric lucifer-
ase/endoglin reporter construct and the miR-
370-3p inhibitor (Chen et al., 2014). Taken 
together, these results indicate that miR-370-
3p can mediate luciferase mRNA transla-
tional repression and/or destabilization by di-
rectly interacting with the predicted miR-
370-3p MRE target site.  
 
Demonstrate miRNA mediated effects on 
target protein expression 
Although the ability of miRNAs to re-
press the activity of a chimeric luciferase re-
porter gene is a useful screening device, it 
remains a surrogate assay for testing the ef-
fects of miRNAs on their putative mRNA 
targets. Therefore, after confirming the phys-
ical interaction of a miRNA with a candidate 
MRE harbored in target mRNAs by reporter 
assays, we recommend that miRNA gain- 
and loss-of-function transfection experi-
ments also be performed to validate miRNA-
mediated post-transcriptional regulation of 
target genes of interest (Figure 2).  
Experimental manipulation of endoge-
nous miRNA activity by miRNA mimic and 
miRNA inhibitor transfection should corre-
spond to predictable changes in target pro-
tein levels (normally by Western blotting, 
ELISA, immunostaining, etc.) (Sansom et 
al., 2010). Therefore, when a given mRNA is 
an authentic miRNA target, transfection of 
that miRNA mimic into a cell type known to 
express the putative target protein, should re-
sult in decreased target protein expression 
due to increased mature miRNA activity 
(i.e., gain-of-function) (Sansom et al., 2010). 
In contrast, transfection of a specific miRNA 
inhibitor into a cell type known to co-express 
the target protein and miRNA of interest, 
should result in augmented target protein ex-
pression as a result of decreased endogenous 
miRNA activity (i.e., loss-of-function) (San-
som et al., 2010). It is important to note that 
loss-of-function experiments can also be 
achieved by utilizing plasmid constructs 
which express mRNAs containing multiple 
artificial miRNA-binding sites, which act as 
decoys or “sponges” (Ebert and Sharp, 
2010). Over-expression of the mRNA-
specific sponges selectively sequesters en-
dogenous miRNAs and as a consequence 
target protein levels increase (Tay et al., 
2015).  
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Although gain- and loss-of-function ex-
periments are powerful, it is important to 
remember that results can be confounded by 
side effects of transfection (Arvey et al., 
2010; Bracken et al., 2008; Khan et al., 
2009) and secondary effects resulting from 
the change in miRNA activity (Matkovich et 
al., 2013; Riba et al., 2014). For example, 
miRNAs may directly or indirectly affect the 
activity of multiple transcription factors 
which in turn can have profound effects on 
transcription that are not the direct result of 
miRNA interaction with mRNA targets 
(Matkovich et al., 2013; Riba et al., 2014). 
The advantage of miRNA inhibitor loss-of-
function experiments is that they will reveal 
whether or not the observed direct interac-
tion of a given miRNA to a specific MRE 
target site, based on the luciferase reporter 
assays, is relevant in the studied biological 
context; not exclusively significant when the 
miRNA is artificially expressed at high lev-
els (Meister et al., 2004; Sansom et al., 
2010). 
The choice of cells utilized for gain- and 
loss-of-function studies is critical as each 
cell line has varying levels of endogenous 
miRNA and target gene expression. It is im-
portant to select a cell culture system that 
expresses an appropriate level of endogenous 
miRNA and target gene so that the effects of 
the miRNA mimics and inhibitors on protein 
levels can be clearly detected. For example, 
since miRNA mimics repress target gene 
protein expression, mimics produce the best 
results in cells that express low levels of en-
dogenous miRNAs and correspondingly high 
target mRNA expression (Sansom et al., 
2010). Under these conditions, when a given 
miRNA mimic is over-expressed, repression 
of the target protein should be easily detect-
able. In contrast, if experiments are per-
formed in cells with high endogenous miR-
NA levels and correspondingly low target 
expression, the effects of miRNA mimic 
over-expression on the target gene may not 
be detectable. Instead, these cells are best for 
investigating the effects of miRNA inhibitors 
since the resulting de-repression of target 
protein expression will be more pronounced 
and easily quantified in these cells.  
While gain- and loss-of-function experi-
ments can be used validate miRNA/mRNA 
target interactions, it is also possible to uti-
lize the IMPACT-Seq experimental method-
ology described in the “Analysis of experi-
mentally validated miRNA/mRNA target da-
ta bases” section above, to independently 
validate whether or not a given miRNA can 
bind to specific mRNAs in vivo (Tan et al., 
2014). Recall that this miRNA ‘‘pull-down’’ 
strategy introduces specific biotinylated 
miRNA mimics into cells and miR-
NA/mRNA targets are pulled down utilizing 
streptavidin (Tan et al., 2014). These prod-
ucts are treated with RNase and the RNase-
resistant fragments are subjected to NGS to 
identify the pulled-down miRNA/mRNA 
targets and to characterize specific MRE(s) 
located within the targeted mRNAs (Tan et 
al., 2014). Alternatively, once the miR-
NA/mRNA targets have been pulled down 
by streptavidin, specific mRNAs can be 
identified by qPCR utilizing primers for the 
gene target of interest (Subramanian et al., 
2015). Therefore, this approach provides a 
means to identify functional miRNA targets 
based on their physical interaction in vivo. 
Since ‘‘predetermined’’ target genes are be-
ing characterized, this procedure could be 
utilized to validate whether or not a given 
mRNA of interest is interacting with a spe-
cific miRNA in vivo. Additionally, these ex-
periments can be used to validate the func-
tional MREs identified by chimeric lucifer-
ase reporter assays described above. Fur-
thermore, miRNA ‘‘pull-down’’ assays can 
also be utilized to identify MREs harbored in 
the 5′-UTR and CDS of target mRNAs. Fi-
nally, given that recent studies have demon-
strated that non-canonical miRNA interac-
tions are more prevalent than previously ap-
preciated, miRNA ‘‘pull-down’’ assays may 
provide a novel way to identify MREs that 
are not predicted by miRNA/mRNA target 
algorithms (Grosswendt et al., 2014; Helwak 
et al., 2013; Martin et al., 2014; Tan et al., 
2014).  
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Chen et al., (2014) demonstrated that 
miR-370-3p could repress the activity of a 
chimeric luciferase/endoglin reporter gene. 
These investigators subsequently performed 
gain- and loss-of-function experiments to de-
termine whether manipulation of endogenous 
miR-370-3p activity corresponded to pre-
dictable changes in endoglin protein expres-
sion. Since the two human endometrioid 
ovarian cancer cell lines (IGROV1 and 
TOV112D), expressed both miR-370-3p and 
endoglin at easily detectable levels, they 
were able to perform gain- and loss-of-
function experiments in each cell line (Chen 
et al., 2014). In miR-370-3p mimic trans-
fected cells human endoglin protein levels 
were repressed. In contrast, human endoglin 
protein levels were augmented in IGROV1 
and TOV112D cells transfected with miR-
370-3p inhibitors. Taken together, these re-
sults suggest that the miR-370-3p can bind to 
the predicted miR-370-3p MRE sequence 
harbored in the 3′-UTR of human endoglin 
mRNA and imply that this interaction is 
physiologically relevant. “Pull-down” exper-
iments were not performed that may have 
proven useful since the Diana-microT-CDS 
algorithm predicted that human S-endoglin 
mRNA harbors an additional miR-370-3p 3′-
UTR MRE whose function is unknown. 
 
Demonstrate miRNA effects on biological 
function 
After miRNA gain- and loss-of-function 
transfection experiments have confirmed that 
a given miRNA mimic and inhibitor mediate 
the inverse protein expression of a target 
gene of interest, it is finally necessary to 
demonstrate that this regulation equates to 
changes in biological function (Figure 2). 
Depending upon the protein target of inter-
est, a variety of biological assays could be 
performed including signaling pathway eval-
uations, cell proliferation, cell differentia-
tion, cell death, cell migration, receptor bind-
ing, etc. (Sansom et al., 2010). Importantly, 
when a biological pathway is being studied, 
phenotypic changes may be assayed as an 
indirect measure of miRNA effects on target 
protein levels (i.e., gain- and loss-of-function 
transfection experiments) as long as the phe-
notypic assay is accompanied by a direct 
protein assay. 
The wide ranging biological effects of a 
given miRNA can also be investigated by 
performing in vivo gain- and loss-of-function 
experiments in mice or rats (reviewed in 
Hinkel et al, 2014; Li and Rana, 2014). For 
example, miRNA function can be increased 
by directly infusing specific miRNA mimics 
(Di Martino et al., 2014a; Montgomery et al., 
2014), by infusing miRNA mimics packaged 
in lipid-based nanoparticles (Das et al., 2014; 
Hsu et al., 2013; Huang et al., 2013), or by 
the use of adeno-associated viruses (AAV) to 
drive the forced-expression of a given miR-
NA (Kasinski and Slack, 2012; Kota et al, 
2009; Miyazaki et al, 2012). In contrast, en-
dogenous miRNAs can be silenced by sys-
temic delivery of cholesterol-conjugated 
miRNA inhibitors, designated “antagomirs” 
(Martin del Campo et al., 2015; McClure et 
al., 2014), by infusing LNA miRNA inhibi-
tors (Di Martino et al., 2014b; Seeger et al., 
2014; Tijsen et al., 2014), or by infusing 
miRNA inhibitors packaged in lipid-based 
nanoparticles (Babar et al., 2012; Baigude 
and Rana, 2012). 
Chen et al. (2014) demonstrated that 
miR-370-3p gain- and loss-of-function ex-
periments inversely regulated endoglin pro-
tein expression. They subsequently per-
formed additional gain- and loss-of-function 
experiments to determine whether or not the 
experimental manipulation of endogenous 
miR-370-3p activity corresponded to observ-
able changes in specific biological responses. 
These experiments demonstrated that miR-
370 mimicry suppressed endometrioid ovari-
an cancer cell malignant phenotypes via the 
negative regulation of endoglin (Chen et al., 
2014). Taken together these investigators 
hypothesized that, in endometrioid ovarian 
cancer cells, hypermethylation reduces miR-
370 levels which in turn results in the elevat-
ed expression of its direct target endoglin. As 
a consequence, endoglin over-expression 
contributes to the enhanced malignant prop-
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erties in endometrioid ovarian cancer cells 
including high proliferation, low apoptosis 
and/or cell death, and enhanced chemo-
resistance. 
 
CONCLUSION 
miRNAs are emerging as important post-
transcriptional regulators of gene expression 
and consequently are central players in many 
physiological and pathological processes 
(e.g., Adams et al., 2014; Iorio and Croce, 
2012; Neppl and Wang, 2014; Trionfini et 
al., 2015). Since the biological roles of 
miRNAs are dictated by the mRNAs that 
they regulate, the identification and valida-
tion of miRNA/mRNA target interactions is 
critical for our understanding of the regulato-
ry networks governing biological processes. 
We advocate the combined use of prediction 
algorithms, the examination of experimental-
ly supported miRNA/mRNA interactions 
cataloged from high throughput experimental 
data sets, manual sequence inspection of cat-
aloged miRNA binding sites in target 
mRNAs, and a review of the published lit-
erature as the optimal practice for identifying 
and prioritizing the most biologically com-
pelling miRNA/mRNA target pairs based on 
individual research interests (Figure 2). For 
effectively utilizing these strategies, through-
out this review, we have used the example of 
miRNA regulation of endoglin.  
Once a preferred miRNA/mRNA target 
pair has been selected, we propose that the 
authenticity of a functional miRNA/mRNA 
target pair be validated by fulfilling four cri-
teria. First, the predicted miRNA and mRNA 
target gene must be co-expressed. Second, 
direct interaction of a given miRNA to a 
specific MRE harbored within the target 
mRNA must be demonstrated. Third, gain- 
and loss-of-function experiments utilizing 
miRNA mimics and inhibitors must inverse-
ly regulate target protein expression. Fourth, 
miRNA-mediated regulation of target gene 
expression (gain- and loss-of-function) 
should equate to altered biological function.  
To date only a small proportion of miR-
NA/mRNA target interactions have been 
functionally validated. The unique experi-
mental outline described here can be applied 
to the validation of any miRNA/mRNA in-
teraction. As relevant targets are identified, 
the biological functions of a specific miRNA 
can be unraveled and assist in development 
of miRNA therapeutics. 
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